China-Belgium biotech Full-Life Technologies has raised $77 million through a mix of $50 million series C equity and $27 million debt financing. The cash will accelerate its radiopharmaceutical ...

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the ...

San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) saw its shares climb by 10.4% to $25.70 in pre-market trading, following its announcement to split into two separate publicly traded companies, ...

US drugmaker AbbVie has announced plans to launch Elahere (mirvetuximab soravtansine-gynx) in the UK at a list price equal to the USA.

US biotech Star Therapeutics, which is developing best-in-class antibodies for bleeding disorders and other diseases, today announced an oversubscribed $125 million Series D financing. This adds to ...

Privately-held French biotech focused on providing immuno-therapeutics Biomunex Pharmaceuticals today announced a capital increase and the investment from new shareholders in equity, actively ...

Shares in Enanta Pharmaceuticals (Nasdaq: ENTA), a US biotech creating small molecule drugs for viral infections and immunological diseases, closed 92% higher Monday. The company earlier announced top ...

US obesity firm Metsera has presented new data that demonstrates why pharma giant Pfizer is paying up to $7.3 billion to buy the company in an acquisition announced last week.

Boston, USA-based biotech Cue Biopharma has announced the appointment of Dr Usman Azam as its new president and chief executive (CEO), supporting the company’s advancement of its first-in-class ...

US eye disease specialist Kala Bio (Nasdaq: KALA) saw its shares close down almost 90% at $2.04 yesterday, after it revealed disappointing trial results for its KPI-012. Due to the failed results, ...

President Donald Trump has called on US industries to put America first, and the biopharmaceutical sector is answering that call with major actions to demonstrate its commitment to American patients ...

Shares of US clinical-stage biotech Dogwood Therapeutics soared a massive 43% to $7.91 yesterday, on the news it has secured a royalty free, global license to develop Serpin Pharma’s intravenous (IV) ...